DHDow P. Hurst

Dow P. Hurst

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Interests


Dow P. Hurst has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Carl A. Carrasquer

    Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky 40292, and Center for Drug Discovery, Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27402

    1 shared publication
  • N. Miranda Nebane

    Preclinical Operations, Southern Research, 2000 Ninth Avenue South, Birmingham, AL, USA

    1 shared publication
  • Patricia H. Reggio

    Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky 40292, and Center for Drug Discovery, Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27402

    1 shared publication
  • Zhao-Hui Song

    Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40292, USA

    1 shared publication
  • Zhuanhong Qiao

    Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky 40292, and Center for Drug Discovery, Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27402

    1 shared publication

Latest Publications

  • Open Access

    Residues Accessible in the Binding-Site Crevice of Transmembrane Helix 6 of the CB2 Cannabinoid Receptor

    by Ntsang M. Nebane, Dow P. Hurst, Carl A. Carrasquer, Zhuanhong Qiao, Patricia H. Reggio, Zhao-Hui Song

    We have used the substituted-cysteine accessibility method (SCAM) to map the residues in the sixth membrane-spanning segment of the CB2 cannabinoid receptor that contribute to the surface of the water-accessible binding-site crevice. Using a background of the mutant C2.59S which is relatively insensitive to the methanethiosulfonate (MTS) reagents, we mutated to cysteine, one at a time, 34 consecutive residues in TMH6 of the CB2 receptor. These mutant receptors were then expressed in HEK293 cells. By incubating HEK293 cells stably transfected with CB2 receptors with the small, charged, hydrophilic, thiol-specific reagent methanethiosulfonate ethylammonium (MTSEA), [3H]CP55940 binding was significantly inhibited for six mutant receptors. All six of the mutants that reacted with MTSEA were protected from the reaction when pretreated with the cannabinoid agonist WIN55212-2, suggesting that MTSEA modification occurred within the binding crevice. Therefore, the side chains of the residues at these reactive loci (V6.51, L6.52, L6.54, M6.55, L6.59, and T6.62) are on the water-accessible surface of the binding-site crevice. These residues are extracellular to the TMH6 CWXP hinge motif. The pattern of accessibility is consistent with a α-helical conformation for this segment of TMH6. Molecular modeling studies performed in the context of the CB2 model show that V6.51, L6.52, L6.54, M6.55, L6.59, and T6.62 face into the CB2 binding pocket, further confirming our SCAM results. These results are similar to the accessibility patterns determined by SCAM studies of TMH6 in the opioid and dopamine D2 receptors.